10% chegirma bering
Maslahat bering ushbu kitobni do'stingiz sotib olganidan 196 276,03 soʻm oling.
matnPDF
Hajm 373 sahifalar
Attrition in the Pharmaceutical Industry
Reasons, Implications, and Pathways Forward
1 962 760,26 soʻm
Kitob haqida
With a focus on case studies of R&D programs in a variety of disease areas, the book highlights fundamental productivity issues the pharmaceutical industry has been facing and explores potential ways of improving research effectiveness and efficiency.• Takes a comprehensive and holistic approach to the problems and potential solutions to drug compound attrition• Tackles a problem that adds billions of dollars to drug development programs and health care costs• Guides discovery and development scientists through R&D stages, teaching requirements and reasons why drugs can fail• Discusses potential ways forward utilizing new approaches and opportunities to reduce attrition
Janrlar va teglar
Izoh qoldiring
Kirish, kitobni baholash va sharh qoldirish
Kitob tavsifi
With a focus on case studies of R&D programs in a variety of disease areas, the book highlights fundamental productivity issues the pharmaceutical industry has been facing and explores potential ways of improving research effectiveness and efficiency.
• Takes a comprehensive and holistic approach to the problems and potential solutions to drug compound attrition• Tackles a problem that adds billions of dollars to drug development programs and health care costs• Guides discovery and development scientists through R&D stages, teaching requirements and reasons why drugs can fail• Discusses potential ways forward utilizing new approaches and opportunities to reduce attrition
Kitob Dennis A. Smith, Alexander Alex va boshqalar «Attrition in the Pharmaceutical Industry» — veb-saytda onlayn o'qing. Fikr va sharhlar qoldiring, sevimlilarga ovoz bering.
Yosh cheklamasi:
0+Litresda chiqarilgan sana:
22 iyun 2018Hajm:
373 Sahifa ISBN:
9781118819449Umumiy o'lcham:
6.1 МБUmumiy sahifalar soni :
373Matbaachilar:
Mualliflik huquqi egasi:
John Wiley & Sons Limited
